Diabetes and endocrine disorders

Neurobiology of Disease

Volumn , Issue , 2007, Pages 669-680

  Pop Busui, Rodica ^a   London, Zachary ^a   Kellogg, Aaron ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884074046     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088592-3/50063-3     Document Type: Chapter

References (27)

1. American Diabetes Association and American Academy of Neurology Consensus statement: report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988, 11:592-597.
2. Dyck P.J., Kratz K.M., Karnes J.L., Litchy W.J., Klein R., Pach J.M., Wilson D.M., O'Brien P.C., Melton L.J., Service F.J. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic N. Neurology 1993, 43:817-824. [published erratum appears in 43, 2345].
3. Control and Complications Trial Research Group Diabetes The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. 1993, 329:977-986. [see comments].
4. U.K.Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998, 352:837-853. [see comments].
5. Stevens M.J., Pop-Busui R., Greene D.A., Obrosova I.G., Feldman E.L. Pathogenesis of diabetic neuropathy. Ellenberg and Rifkin's Diabetes Mellitus 2002, 741-770. Appleton & Lange, Waltham, Mass. D. Porte (Ed.).
6. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl. J. Med. 2003, 348:383-393.
7. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., Wright A.D., Turner R.C., Holman R.R. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. B. Med. J. 2000, 321:412-419.
8. Tesfaye S., Chaturvedi N., Eaton S.E., Ward J.D., Manes C., Ionescu-Tirgoviste C., Witte D.R., Fuller J.H. Vascular risk factors and diabetic neuropathy. New Engl. J. Med. 2005, 352:341-350.
9. Pop-Busui R., Sima A., Stevens M.J. Diabetic neuropathy and oxidative stress. Diabetes, Metabolism Research Reviews 2006, 22:257-273.
10. Brownlee M. A radical explanation for glucose-induced beta cell dysfunction. J. Clin. Invest. 2003, 112:1788-1790.
11. Boulton A.J., Malik R.A., Arezzo J.C., Sosenko J.M. Diabetic somatic neuropathies. Diabetes Care 2004, 27:1458-1486.
12. Low P.A., Ward K., Schmelzer J.D., Brimijoin S. Ischemic conduction failure and energy metabolism in experimental diabetic neuropathy. Am. J. Physiol. 1985, 248:E457-E462.
13. Boulton A.J., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., Malik R.A., Maser R.E., Sosenko J.M., Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
14. Sima A.A., Kamiya H., Li Z.G. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. Eur. J. Pharmacol. 2004, 490:187-197.
15. Vincent A.M., Brownlee M., Russell J.W. Oxidative stress and programmed cell death in diabetic neuropathy. Ann. NY Acad. Sci. 2002, 959:368-383.
16. Russell J.W., Sullivan K.A., Windebank A.J., Feldman E.L. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol. Dis. 1999, 6:347-363.
17. Cheng C., Zochodne D.W. Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 2003, 53:2363-2371.
18. Stevens M.J., Raffel D.M., Allman K.C., et al. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomograph. Metabolism 1999, 48:92-101.
19. 123I] metaiodobenzylguanidine scintigraphy: a 4-year prospective study in I. Diabetologia 1998, 41:443-451.
20. Pop-Busui R., Kirkwood I., Schmid H., Marinescu V., Schroeder J., Larkin D., Raffel D., Stevens M.J. Sympathetic dysfunction in type I diabetes: implications for cardiovascular injury. JACC 2004, 44:2368-2374.
21. DCCT Study Group Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann. Neurol. 1995, 38:869-880.
22. Anagnos A., Ruff R.L., Kaminski H.J. Endocrine neuromyopathies. Neurol. Clin. 1997, 15:673-696.
23. Kaminski H.J., Ruff R.L. Neurologic complications of endocrine diseases. Neurol. Clin. 1989, 7:489-508.
24. Wolkowitz O.M. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology 1994, 19:233-255.
25. Ubogu W., Ruff R.L., Kaminski H.J. Endocrine myopathies. Myology 2004, 1713-1738. McGraw-Hill, Stamford, Conn. A.G. Engel (Ed.).
26. Gelb, D. Hypothyroidism, S. G., Ed. Medlink Neurology, www.med-link.com, San Diego.
27. Pollard J.D. Neuropathy in disease of the thyroid and pituitary glands. Peripheral Neuropathy 2005, 2039-2049. Saunders, New York. P. Dyck (Ed.).